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Tuberculosis case detection revisited: better testing might 
not improve outcomes 
Tuberculosis case-ﬁ nding and diagnostics are far 
from perfect. The worldwide case detection rate of 
tuberculosis has stagnated at around 60%, not reaching 
the target of 70% originally set for 2000 but postponed 
to 2005, and then judged to be unreachable.1 In sub-
Saharan Africa, case detection rates are as low as 52%.2 
Diagnosis of tuberculosis in high-endemic low-income 
areas has been, and still is, a challenge. Although the 
gold standard for tuberculosis diagnosis is sputum 
culture, which takes time and relies on a consistent 
power supply, many settings are still reliant on sputum 
smear microscopy, a 125-year-old method that fails 
to detect up to 50% of cases––even more if laboratory 
capacity is exceeded, as is often the case in low-resource 
settings. Since WHO has recommended Xpert MTB/
RIF, it has been used by 108 of the 145 countries that 
were eligible for concessional pricing.2 From the initially 
recommended use in people at risk of multidrug-
resistant  tuberculosis and HIV-infected patients, current 
guidelines encourage use of Xpert MTB/RIF for all people 
with suspected tuberculosis.3
In The Lancet Global Health, Gavin Churchyard and 
colleagues4 report the results of XTEND, a cluster-
randomised trial testing the eﬀ ect of Xpert MTB/RIF on 
patient-relevant outcomes in the context of routine 
implementation. The XTEND trial was embedded 
in the national South African rollout of Xpert MTB/
RIF and compared the eﬀ ect of XPERT MTB/RIF with 
ﬂ uorescence microscopy on outcomes such as mortality 
at 6 months, proportion of positive cases, and the 
proportion of patients investigated for tuberculosis who 
started treatment. 
Churchyard and colleagues enrolled 4712 participants 
with suspicion of tuberculosis and observed no 
diﬀ erence between the study groups in mortality, 
proportion starting tuberculosis treatment, or initial 
loss to follow-up. They did, however, note a 50% higher 
rate of people with bacteriological conﬁ rmation of 
tuberculosis in the Xpert group, thus allowing a reduced 
time to treatment initiation.
The eﬀ ect of routine implementation of Xpert MTB/RIF 
was also recently assessed in the TB-NEAT trial;5 however, 
compared with the TB-NEAT trial, which used morbidity 
as an outcome as assessed by the Bandim TBscore,6 
XTEND was a more robust evaluation in more real-life 
settings. The XTEND trial, therefore, adds important 
insights and conﬁ rms the somewhat disappointing 
ﬁ ndings of the TB-NEAT trial in a setting even closer 
to reality, in that the decision to refer to tuberculosis 
diagnostics was left to health-care staﬀ , and existing 
diagnostic pathways were not altered. The XTEND trial 
could, therefore, inform those who make decisions for 
country programmes about when and how to invest 
in new diagnostic tests for tuberculosis. Importantly, 
the XTEND trial draws attention to the importance of 
simultaneously strengthening health systems alongside 
introduction of new diagnostic methods to reduce initial 
loss to follow-up.
So, why did rollout of Xpert MTB/RIF not have an eﬀ ect 
on mortality at 6 months? Most deaths were HIV related, 
and many patients were unaware of their HIV status 
or were not taking antiretroviral therapy if they were 
known to be HIV positive. Furthermore, the eﬀ ect of 
averting tuberculosis deaths through earlier diagnosis 
and treatment might be diﬃ  cult to show in such a setting 
and with a relatively short 6 month follow-up period. 
Churchyard and colleagues’ ﬁ ndings are an important 
lesson that no new diagnostics can overcome gaps in 
weak health-care systems, so roll-out of prompt linkage 
to HIV care or immediate tuberculosis treatment for all at 
the time and place of diagnosis might be more important 
than the introduction of new technological solutions.
Another observation from the XTEND trial is that all 
enrolled participants were adults seeking health care 
and who had sputum smear tests requested by clinic 
staﬀ . Thus, the authors were reliant on the health-care 
providers’ initial suspicions of tuberculosis and referral 
for testing. Referral rates are often low because of 
very broad case deﬁ nitions for tuberculosis7 and high 
thresholds for referral,8 and many patients who are 
later diagnosed with tuberculosis are initially missed.9 
Improvements in the rates of relevant patients with 
suspected tuberculosis being referred for these new 
diagnostics are, therefore, urgently needed, and 
implementation of trials of relevant algorithms8 should 
be a priority. Staﬀ  at clinics who had received training 
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during the implementation of Xpert MTB/RIF did refer 
slightly healthier patients than did clinics where training 
had not yet been given, which indicates that training of 
staﬀ  in how to detect the more insidious tuberculosis 
cases is needed to tackle the global tuberculosis burden.
The implementation of Xpert MTB/RIF will not 
be possible in all high-endemic settings because it 
requires a stable power supply and a constant supply of 
cartridges. The current implementation is mainly donor 
funded, largely dependent on testing in centralised 
laboratories, and mostly involves patients with 
presumed drug-resistant tuberculosis or HIV infection.10 
Nevertheless, Xpert MTB/RIF is now being rolled out in 
many settings, and it is important to remember, could 
increase detection rates if implementation is done 
strategically and well. Yet, every diagnostic assessment 
depends on clinical suspicion and referral for testing by 
a health worker. The challenge in providing better case-
ﬁ nding is, therefore, to ensure that overwhelmed and 
undertrained health staﬀ  at the front line have: ﬁ rst, 
good algorithms for referral in order to improve triage of 
those seeking health care for symptoms of tuberculosis; 
second, good point-of-care diagnostics; and, third, 
health systems with linkage between diagnostics and 
treatment for not only tuberculosis but also HIV. 
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